Application Of Interferon Gamma Release Assays To Patients With Acid-fast Bacilli Positive Pulmonary Diseases And Analysis Of Drug-sensitivity

Objective: To analyze the role of interferon gamma release assays(IGRAs)in diagnosis of acid-fast bacilli positive pulmonary diseases as well as the result of drug sensitivity test so as to provide a reference for clinical treatment of the diseases.Methods: The sputum,pleural effusion,tissue biopsy and alveolar lavage fluid of 325 patients with acid-fast bacilli positive pulmonary diseases in The Second Affiliated Hospital of Chongqing Medical University and the People’s Hospital of Chongqing were collected from January 2015 to December 2016 and subjected to identification of mycobacterium,IGRAs and drug sensitivity test.Results: Of the 325 cases acid-fast bacilli positive pulmonary diseases,308(94.8%)were positive for Mycobacterium tuberculosis(MTB)while 17(5.2%)for non-tuberculosis mycobacteria(NTM).The sensitivity of IGRAs to diagnosis of MTB pulmonary diseases was 85.1%,while that to NTM pulmonary diseases was 88.2%.The resistance rate of MTB to first-line anti-tuberculosis drugs was higher than that to second-line drugs(P<0.05).However,most of NTM were highly resistant to first-line anti-tuberculosis drugs.Conclusion: The patients with acid-fast bacilli positive pulmonary diseases should be subjected to identification of mycobacterium and drug sensitivity test so as to treat MTB and NTM accurately.